Analyst Price Targets — BLLN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 29, 2026 10:59 am | — | Guggenheim | $125.00 | $118.17 | TheFly | BillionToOne price target raised to $125 from $120 at Guggenheim |
| May 7, 2026 12:08 pm | — | BTIG | $130.00 | $82.83 | TheFly | BillionToOne price target lowered to $130 from $140 at BTIG |
| March 5, 2026 2:20 pm | Mark Massaro | BTIG | $140.00 | $72.66 | StreetInsider | BillionToOne Inc (BLLN) PT Lowered to $140 at BTIG |
| January 6, 2026 11:45 am | — | Guggenheim | $120.00 | $95.00 | TheFly | BillionToOne initiated with a Buy at Guggenheim |
| December 1, 2025 11:11 am | Mark Massaro | BTIG | $160.00 | $130.18 | TheFly | BillionToOne initiated with a Buy at BTIG |
| December 1, 2025 10:06 am | — | Wells Fargo | $110.00 | $130.18 | TheFly | BillionToOne initiated with an Equal Weight at Wells Fargo |
| December 1, 2025 9:41 am | — | Stifel Nicolaus | $145.00 | $130.18 | TheFly | BillionToOne initiated with a Buy at Stifel |
| December 1, 2025 7:45 am | David Westenberg | Piper Sandler | $150.00 | $130.18 | StreetInsider | Piper Sandler Starts BillionToOne Inc (BLLN) at Overweight |
| December 1, 2025 7:43 am | Tycho Peterson | Jefferies | $117.00 | $130.18 | StreetInsider | Jefferies Starts BillionToOne Inc (BLLN) at Hold |
Latest News for BLLN
New add-on test from a single blood draw; BillionToOne also expands Northstar Select® panel to 102 genes MENLO PARK, Calif., Sept. 1, 2026 /PRNewswire/ -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the launch of Northstar Origin™, a new liquid biopsy add-on test for…
The transaction involved 10,000 shares at a weighted-average price of $100.00 per share, totaling $1.0 million on the August 25, 2026 transaction date. Following the disposal, the insider holds a direct position of 1,000 shares, which represents approximately 0.0022% of the company's total shares outstanding.
/C O R R E C T I O N -- BillionToOne/ PR Newswire MENLO PARK, Calif., Aug. 18, 2026 I
Study of more than 2,200 pregnant carriers demonstrates strong clinical performance in the intended-use, general-risk population, with outcomes available for more than 98% of eligible cfDNA results MENLO PARK, Calif., Aug. 18, 2026 /PRNewswire/ -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today…
Billiontoone, Inc. (NASDAQ: BLLN - Get Free Report) has been given a consensus rating of "Moderate Buy" by the ten analysts that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and six have issued a buy recommendation on the company.
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for BLLN.
Senate Trading
No Senate trades found for BLLN.
U.S. House Trading
No House trades found for BLLN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.